The efficacy of pharmaceutical aerosols relates to its deposition in the clinically relevant
regions of the lungs, which can be assessed by in vivo lung deposition studies. Dry powder …

In the last decades, dry powder inhalation has become a very attractive option for pulmonary
drug delivery to treat lung diseases like cystic fibroses and lung infections. In contrast to the …

This review examines the key issues surrounding the development and preparation of
formulations for dry powder inhalers. The various inhaler devices that are currently available …

The pulmonary route is an interesting route for drug administration, both for effective local
therapy (asthma, chronic obstructive pulmonary disease or cystic fibrosis) and for the …

Pulmonary drug delivery is the focus of much research and development because of its
great potential to produce maximum therapeutic benefit. Among the available options the dry …

The inhalation of aerosolised drug has become a well established treatment modality in
conditions such as asthma. The pressurised metered-dose inhaler (MDI) is still the most …

Dry powder inhalers (DPIs) are a widely accepted inhaled delivery dosage form, particularly
in Europe, where they currently are used by a large number of patients for the delivery of …

Dry powder inhalers (DPIs) are an important and increasingly investigated method of
modern therapy for a growing number of respiratory diseases. DPIs are a promising option …

The pulmonary route has long been used for drug administration for both local and systemic
treatment. It possesses several advantages, which can be categorized into physiological, ie …

In recent years there is an increasing interest in the pulmonary delivery of large cohesive
powder doses, ie drugs with a low potency such as antibiotics or drugs with a high potency …